Epstein-Barr virus does not leave your body once you’re infected. The acute illness it causes, most commonly mono, resolves within a few weeks to months, but the virus itself takes up permanent residence in your immune cells and stays there for life. Close to 95% of adults worldwide carry EBV, and the vast majority never have symptoms again after the initial infection clears.
That said, “carries the virus forever” and “is sick forever” are very different things. Understanding what the virus actually does after you recover can help you make sense of blood test results, occasional flare-ups, and the long-term health links researchers are still untangling.
How the Acute Illness Resolves
When EBV causes infectious mononucleosis, most people recover in two to four weeks. Fatigue often lingers longer, sometimes several additional weeks beyond the point where fever, sore throat, and swollen lymph nodes have cleared. In a smaller number of cases, symptoms can stretch to six months or more, but this is the exception.
During the acute phase, your immune system mounts an aggressive response that brings the active infection under control. The virus isn’t destroyed, though. Instead, it shifts into a dormant state, essentially going quiet inside a specific type of white blood cell.
Where the Virus Hides Long-Term
EBV is a herpesvirus, and like all herpesviruses, it has evolved to persist indefinitely in the body. Its hiding place is memory B cells, a subset of immune cells that circulate in your blood and are designed to live for decades. The virus tucks its genetic material into these cells as a small, self-replicating loop of DNA and expresses only a handful of genes, just enough to copy itself when the host cell divides. This minimal footprint keeps it largely invisible to the immune system.
Researchers have identified several distinct “latency programs” that EBV can switch between, varying how many viral genes are active at any given time. In its quietest state (called type 0 latency), the virus expresses almost nothing at all. This is why a healthy person can carry billions of infected B cells without feeling a thing.
Reactivation: When the Virus Wakes Up
The dormant virus can periodically reactivate, shifting from its silent state back into active replication. This happens when cell-mediated immunity drops, whether from psychological stress, physical illness, sleep deprivation, or medications that suppress the immune system.
Most reactivation episodes are subclinical, meaning you won’t notice symptoms. Your immune system detects the uptick in viral activity and shuts it down quickly. But these episodes do produce detectable virus. In a six-month study of healthy adults who carried EBV, every single participant shed viral DNA in their saliva at least once during the study period. About 24% of all oral samples tested positive for EBV DNA. Younger adults (18 to 30) shed the virus significantly more often than those over 30.
One participant in that study had detectable virus in their blood continuously for 79 days, all while remaining completely healthy. This kind of silent shedding is normal and is the primary way the virus spreads to new hosts through saliva.
How Blood Tests Reflect Past Infection
If you’ve had blood work done for EBV, the results can look alarming if you don’t know what the different antibody markers mean. Here’s what each one tells you:
- VCA IgM: This antibody appears early in a new infection and typically disappears within four to six weeks. If it’s positive, you’re likely in the acute phase.
- VCA IgG: This peaks a few weeks after infection, dips slightly, then stays positive for the rest of your life. A positive result alone just means you were infected at some point.
- EBNA antibody: This develops slowly, appearing two to four months after symptoms start, and persists for life. If you have both VCA IgG and EBNA antibodies, it confirms a past infection, not an active one.
- EA IgG: This antibody rises during active infection and generally falls to undetectable levels within three to six months. When it shows up, it often signals active replication, either a new infection or a reactivation.
A common source of confusion: seeing a positive VCA IgG result and thinking you currently have an active infection. That antibody simply never goes away. It’s a permanent marker of past exposure, not ongoing illness.
When EBV Doesn’t Stay Quiet
In rare cases, EBV causes a condition called chronic active EBV disease (CAEBV). This is not the same as normal viral latency or the lingering fatigue some people experience after mono. CAEBV involves the virus infecting types of immune cells it doesn’t normally target (T cells and natural killer cells), leading to persistent inflammation and organ damage.
The diagnostic criteria require mono-like symptoms lasting more than three months, unusually high levels of viral DNA in the blood, and confirmed EBV infection in T or NK cells. People with CAEBV can develop serious complications including liver failure, blood vessel inflammation, and a dangerous immune overreaction called hemophagocytic lymphohistiocytosis. CAEBV is extremely uncommon and is a fundamentally different situation from the normal lifelong carriage that 95% of adults experience without problems.
No Approved Treatment to Eliminate EBV
There is currently no antiviral drug approved to treat or eliminate EBV. Several antivirals can inhibit the virus from replicating in lab settings, but clinical trials have been largely ineffective. The core problem is that antiviral drugs target the virus during active replication, and latent EBV sitting quietly inside B cells isn’t replicating in a way these drugs can reach. Treating EBV remains, as researchers have described it, “a major unmet medical need.”
For acute mono, treatment is supportive: rest, fluids, and pain relief. For CAEBV, some patients receive immune-modulating therapies, though with limited success. No available medication can clear the latent virus from memory B cells.
Long-Term Health Associations
The most striking long-term connection is between EBV and multiple sclerosis. A landmark study tracking 10 million individuals found that the risk of developing MS rises 32-fold after EBV infection, and people who have never been infected with EBV have a vanishingly small chance of developing the disease. Over 99% of people with MS carry EBV, compared to about 95% of the general population. Those with the highest antibody levels against certain EBV proteins face up to a 36-fold increased risk.
Genetic factors compound this. Carrying a specific immune system gene variant, combined with elevated EBV antibodies, increases MS risk 15-fold. Adolescent obesity paired with EBV infection raises risk 14-fold. These interactions suggest that EBV is necessary but not sufficient on its own for MS to develop.
EBV is also causally linked to at least seven types of cancer, and elevated EBV antibodies appear in higher-than-expected levels in people with rheumatoid arthritis, lupus, and Sjögren’s disease. Researchers are still working to determine whether the virus directly triggers these conditions or whether it interacts with genetic and environmental factors in ways that tip the balance toward disease.
For the vast majority of people, carrying EBV is biologically unremarkable. Your immune system keeps the virus in check, reactivation episodes come and go without symptoms, and the virus simply becomes one of many microorganisms your body quietly manages for the rest of your life.